These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15349013)

  • 1. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
    Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
    J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV; Eaddy MT; Shah MB; Mauch RP
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
    Endicott J; McLaughlin TP; Grudzinski AN
    J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
    Keene MS; Eaddy MT; Nelson WW; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S362-9. PubMed ID: 16236018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors.
    Eaddy M; Bramley T; Regan T
    Manag Care Interface; 2003 Dec; 16(12):22-7. PubMed ID: 14750459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE; Regan TS; Chiao E; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
    Crown WH; Treglia M; Meneades L; White A
    Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center.
    Singletary T; North DS; Weiss M; Marman G
    Am J Manag Care; 1997 Jan; 3(1):125-9. PubMed ID: 10169244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A; Devine ST; Eichholz J; Kautzner A
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
    Panzarino PJ; Xuan J
    Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Paroxetine versus clomipramine in female adolescents suffering from anorexia nervosa and depressive episode--a retrospective study on tolerability, reasons for discontinuing the antidepressive treatment and different outcome measurements].
    Strobel M; Warnke A; Roth M; Schulze U
    Z Kinder Jugendpsychiatr Psychother; 2004 Nov; 32(4):279-89. PubMed ID: 15565897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
    Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
    Manag Care Interface; 2002 Jun; 15(6):24-30. PubMed ID: 12087603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
    Roy-Byrne PP; Clary CM; Miceli RJ; Colucci SV; Xu Y; Grudzinski AN
    J Clin Psychiatry; 2001 Sep; 62(9):678-82. PubMed ID: 11681762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.